register free | resend password


Innoplexus Announces Appointment of Rita Kelley as Senior Vice President and Managing Director, USA

ID: 1552243
recent pressrelease next pressrelease

(PresseBox) - Innoplexus Inc, a subsidiary of Innoplexus AG, Frankfurt, which has developed the most comprehensive, industry-validated, AI-powered Drug Discovery and Development platform, announced today the appointment of Rita Kelley as Senior Vice President Corporate Development and Marketing. Rita will also act as Managing Director USA. Ms. Kelley is highly accomplished biotechnology and pharmaceutical executive with more than 20 years of leadership experience across strategy, commercial, and business development functions.

?We are extremely pleased that Rita has chosen to join Innoplexus at this exciting time in the company?s development,? said Dr. Gunjan Bhardwaj, Founder, and CEO of Innoplexus. ?Rita?s extensive expertise will be crucial for Innoplexus as we plan for the commercial growth of our platform. Innoplexus has an industry-validated, AI-powered, Drug Discovery, and Development platform that?s creating value for diverse stakeholders such as Pharma, Biotechs, CROs, Research Organizations, Patients, Governments and Investors by driving innovation in science, clinical development, and commercialization.

Prior to joining Innoplexus, Ms. Kelley served as Vice President of Medical and Commercial Strategy at BioNTech SE, where she helped build and significantly grow the novel mRNA immunotherapy pipeline in cancer and rare diseases.

?I am very excited to be joining the Innoplexus team. Innoplexus has the ability to drive a paradigm shift in drug discovery and development, which in turn will bring life-transforming medicines to patients across the globe faster?, said Ms. Kelley.

Ms. Kelley has held senior executive global positions at Pfizer, Novartis, and Merck, where she led the global effort that successfully achieved the historic, first in class, best in class approval of Keytrudainess revenues through the identification of new pathways across multiple indications.

Innoplexus AG is a leading global AI-champion with over 300 employees and 90+ patent applications in Artificial Intelligence, Machine Learning, and Blockchain technologies. Innoplexus applies its proprietary tech stack in all stages of the drug development value chain via smart Data as a Service (DaaS) and Continuous Analytics as a Service (CaaS) solutions. Generating real-time insights from 100s of Terabytes of structured and unstructured private and public data, Innoplexus helps organizations move towards continuous decision-making. Founded in 2015, Innoplexus AG is headquartered in Eschborn, Germany with offices in Pune, India, and Hoboken, USA.





More information:
http://https://



Keywords (optional):



Company information / Profile:

Innoplexus AG is a leading global AI-champion with over 300 employees and 90+ patent applications in Artificial Intelligence, Machine Learning, and Blockchain technologies. Innoplexus applies its proprietary tech stack in all stages of the drug development value chain via smart Data as a Service (DaaS) and Continuous Analytics as a Service (CaaS) solutions. Generating real-time insights from 100s of Terabytes of structured and unstructured private and public data, Innoplexus helps organizations move towards continuous decision-making. Founded in 2015, Innoplexus AG is headquartered in Eschborn, Germany with offices in Pune, India, and Hoboken, USA.

PressRelease by

Requests:



PressContact / Agency:



published by: PresseBox
print pressrelease  send to a friend  

Date: 09/17/2019 - 08:00
Language: English
News-ID 1552243
Character count: 2947
Kontakt-Informationen:
Firma: Innoplexus AG
Ansprechpartner: Feedback to businesspress24.com about Pressrelease-id:
Stadt: Eschborn
Telefon:

Meldungsart:
Versandart:
Freigabedatum:
Comments:



Number of hits: 172

Linking-Tips:



Direct Link to this PressRelease:






We would appreciate a link in your News-, Press- or Partner-Site.

Comments on this PressRelease






All members: 9 418
Register today: 1
Register yesterday: 7
Members online: 0
Guests online: 43


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.